Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director · CEO | July 27, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date July 27, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 98,845 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Gift · Disposed 319.6499 · Balance 98,845 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 11,836.201 |
Reported balance
After 2026-07-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-07-27 · Gift · Acquired 319.6499 · Balance 11,836.201 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 8,915.6499 |
Reported balance
After 2026-07-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-07-27 · Sale · Disposed 2,920.5511 · Balance 8,915.6499 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 3,733.5603 |
Reported balance
Holding disclosure · report date 2026-07-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,733.5603 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 27, 2026 22:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,920.5511 | $83.93 | $245,134.12 |
DisclosureSEC source: 0001225208-26-006743 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 8,915.6499 Read SEC document |
| July 27, 2026 Filed Jul 27, 2026 22:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 319.6499 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-006743 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 11,836.201 Read SEC document |
| July 27, 2026 Filed Jul 27, 2026 22:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 319.6499 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-006743 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,845 Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 00:19 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 523 | $87.92 | $45,982.16 |
DisclosureSEC source: 0001225208-26-006103 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 11,516.5511 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. Read SEC document |
| May 12, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 35,506 | $77.92 | $2,766,762.44 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 12,039.5511 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $77.375 to $78.360. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 845 | $78.40 | $66,250.28 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 5 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 47,545.5511 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $78.390 to $78.430. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 26,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 48,390.5511 Read SEC document |
| May 12, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 26,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,164.6499 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 21,750.5511 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 5 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,795.6499 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 47,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · derivative · entry 8 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F5 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 26,198 | $79.96 | $2,094,792.08 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,804.6499 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 47,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,491.6499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 16,261.5511 Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 5,398 | $82.76 | $446,738.48 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,284.6499 Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,682.6499 Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 43,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · derivative · entry 10 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock · 43,800 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 245,300 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · derivative · entry 9 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,300 Underlying: Common Stock · 245,300 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,153 | $83.20 | $345,529.60 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,904.6499 Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 43,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,057.6499 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004968 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 12,039.5511 Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004968 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,257.6499 Read SEC document |
| May 03, 2026 Filed May 5, 2026 23:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 515 | $83.98 | $43,249.70 |
DisclosureSEC source: 0001225208-26-004968 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,780.6499 Read SEC document |
| February 13, 2026 Filed Feb 13, 2026 22:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-001893 · doc4.xml · nonDerivative · entry 5 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 11,516.5511 Read SEC document |
| February 13, 2026 Filed Feb 13, 2026 22:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-001893 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,976 Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,350 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-001893 · doc4.xml · derivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,350 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 19,898 | $76.61 | $1,524,451.44 |
DisclosureSEC source: 0001225208-26-001893 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,896 F2 · price: This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,532 | $77.13 | $195,289.87 |
DisclosureSEC source: 0001225208-26-001893 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,794 F1 · price: This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 22:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,350 | $59.26 | $1,502,157.35 |
DisclosureSEC source: 0001225208-26-001893 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,863 | $83.45 | $322,367.35 |
DisclosureSEC source: 0001225208-25-009840 · doc4.xml · nonDerivative · entry 5 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 8,596.5511 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 3,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-009840 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 12,459.5511 Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 3,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-009840 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,976 Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 25,350 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-25-009840 · doc4.xml · derivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,350 Underlying: Common Stock · 25,350 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 21,487 | $85.21 | $1,831,006.11 |
DisclosureSEC source: 0001225208-25-009840 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,839 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.63 to $85.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 23:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 25,350 | $59.26 | $1,502,157.35 |
DisclosureSEC source: 0001225208-25-009840 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 21:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 967 | $77.32 | $74,771.53 |
DisclosureSEC source: 0001225208-25-005684 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 8,596.5511 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.140 to $77.540 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,099 | $77.21 | $1,243,064.97 |
DisclosureSEC source: 0001225208-25-005684 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 9,563.5511 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.930 to $77.585 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 16, 2025 Filed May 16, 2025 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,815.5511 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-005233 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 25,662.5511 F1 · kind: This transaction involved the reporting person's transfer of 5,815.5511 shares of EW common stock directly held to the reporting person's Family Trust for no consideration. Read SEC document |
| May 16, 2025 Filed May 16, 2025 22:22 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 5,815.5511 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-005233 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,976 F1 · kind: This transaction involved the reporting person's transfer of 5,815.5511 shares of EW common stock directly held to the reporting person's Family Trust for no consideration. Read SEC document |
| May 13, 2025 Filed May 13, 2025 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-005052 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 19,847 Read SEC document |
| May 13, 2025 Filed May 13, 2025 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 2,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-005052 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,791.5511 Read SEC document |
| May 11, 2025 Filed May 13, 2025 21:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 2,860 | $73.68 | $210,724.80 |
DisclosureSEC source: 0001225208-25-005052 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,562.5511 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 43,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · derivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,550 Underlying: Common Stock · 43,550 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 244,400 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · derivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,400 Underlying: Common Stock · 244,400 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 4,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 17,076 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 4,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,422.5511 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 43,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,544.5511 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 4,253 | $74.92 | $318,634.76 |
DisclosureSEC source: 0001225208-25-004941 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,994.5511 Read SEC document |
| May 06, 2025 Filed May 6, 2025 21:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 8 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 12,954 Read SEC document |
| May 06, 2025 Filed May 6, 2025 21:13 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004799 · doc4.xml · nonDerivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,247.5511 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.